.png)
Why we focus on fighting antimicrobial resistance and how we do it.
AMR is a serious global health threat.
Antimicrobial resistance is a serious health crisis, responsible for over one million deaths each year. Projections suggest it could lead to 39 million deaths by 2050 and cause a 2-3.5% reduction in global GDP.
We need a continuous pipeline of new antibiotics coming to market to replace those which are no longer effective.
We can combat this rising threat on two main fronts:
-
Reduction of the rate at which bacteria (and other microbes) develop resistance.
-
Development of new antimicrobials that are effective against resistant infections.
Given the unclear drivers of resistance and the limited short-term impact of stewardship efforts, we focus on incentives for the development of new antibiotics.
Market incentives have failed to stimulate the needed innovation.
Due to a variety of challenges, market incentives have failed to stimulate the needed innovation.
This unsustainable market has driven most large pharmaceutical companies out of antimicrobial R&D, and much of the skills and expertise that were built up there is lost. Without urgent change, we are looking at the collapse of the antimicrobial pipeline within 4 to 8 years.
To address market failure,
a combination of push and pull incentives is needed.
PUSH INCENTIVES
Aim to support research and development from the early stages to clinical trials, regardless of successful access to the market.
It involves lowering developers’ costs and risks through financial, tax, and regulatory incentives.
PULL INCENTIVES
Financial rewards for companies that bring new antimicrobials to market.
Investing in pull incentives for 18 new antibiotics over 30 years could save 9.9 million lives and generate $4.9 trillion in benefits, with a 125:1 ROI.
R&D is only part of the solution, we need global access!
To ensure widespread access, ARMoR supports global access conditionalities, which tie access requirements to government and philanthropic funding for antimicrobial R&D.
We advocate for strategies such as pooled procurement and regulatory harmonisation to enhance global access.